HOME >> MEDICINE >> NEWS
Possible treatment found for 'chemobrain'

Patients who take medication for cancer often find themselves with a new problem when their treatment ends.

It's called "chemobrain," a common consequence of chemotherapy that causes memory problems, confusion and difficulty in concentrating.

Symptoms of chemobrain can also include lack of focus, inability to organize daily activities, mental confusion, memory loss and decreased mental clarity.

It's estimated that chemobrain occurs in as many as 99 percent of breast and ovarian cancer patients receiving chemotherapy or radiation treatments. Sixty-one percent of these patients continue to experience fatigue and memory problems long after their cancer treatment has stopped.

Now, researchers led by the University of Cincinnati's (UC) Elyse Lower, MD, report a possible new treatment for the problem using the drug dexmethyphenidate (d-MPH).

Dr. Lower, professor of hematology/oncology at UC College of Medicine, recently described the encouraging results of a 14-month, multi-center, Phase 2 study of d-MPH to the annual meeting of the American Society of Clinical Oncology.

The 154 cancer survivors at 21 medical centers showed significant reduction in fatigue and improvement in memory when treated with dosages of 10 mg to 50 mg of d-MPH per day, Dr. Lower said, when compared with a control group receiving a placebo.

All the patients, who had a median age of 53 years, had completed at least four cycles of chemotherapy at least two months before the study began. Ninety percent of them were female (76 percent with breast cancer and 14 percent with ovarian cancer), 79 percent were white and 9 percent were African-American.

"The study showed that up to 50 mg a day of d-MPH is safe and effective for relieving chemobrain in adult cancer patients," said Dr. Lower, "and it should be considered as a treatment."

One of the study participants, Marilyn Metz, had undergone radiation and chemotherapy in 2001 to t
'"/>

Contact: Sheryl Hilton
sheryl.hilton@uc.edu
513-558-4561
University of Cincinnati
7-Jun-2005


Page: 1 2

Related medicine news :

1. Possible new breast cancer gene
2. Possible predictors of relationship violence
3. Possible exposure to nerve agents and brain cancer deaths in Gulf War veterans
4. Spot on treatment for acne
5. New treatment boosts muscle function in myasthenia gravis
6. New treatment effective in counteracting cocaine-induced symptoms
7. UCLA researchers awarded $9M contract for study identifiying antibiotic treatment for MRSA
8. Preventive treatments in elderly people needs rethinking
9. Osteoporosis screening and treatment may be cost-effective for selected older men
10. Quality of treatment guidelines
11. Green tea holds promise as new treatment for inflammatory skin diseases

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/28/2017)... (PRWEB) , ... July 28, 2017 , ... Kevin Harrington, one of the original Sharks ... announce the launch of a new DRTV campaign with My Real Earth. , Most people ... our bodies is just as important as what we put in our bodies. After all, ...
(Date:7/28/2017)... ... July 28, 2017 , ... For over 20 years Sealy Baby has been ... babies. We take tremendous pride in using some of nature’s best materials while integrating ... and innovative crib mattresses and crib bedding for infants and ...
(Date:7/27/2017)... , ... July 27, 2017 , ... ... through an alliance of independent physicians, has launched a new educational series of ... Jersey’s new regulations governing the prescribing of pain medication. The first two episodes ...
(Date:7/27/2017)... ... July 27, 2017 , ... Patients with ... in a single office visit from Dr. Alejandro Kovacs. Dr. Kovacs is a ... East Texas patients, including Teeth-in-a-Day® dental implants in Longview, TX. ...
(Date:7/27/2017)... , ... July 27, 2017 , ... ... Verification to State Medicaid programs, Managed Care Organizations and Home Care Agencies, has ... The MEDsys platform, VinCENT, provides technology solutions to over 1,000 agencies and multiple ...
Breaking Medicine News(10 mins):
(Date:7/12/2017)... Lilly and Company (NYSE: LLY ) has entered ... patent litigation in the U.S. District Court for the Eastern ... ® (tadalafil) unit dose patent. This patent was previously ... the agreement, Cialis exclusivity is now expected to end at ... dose patent for Cialis is valid and infringed by companies ...
(Date:7/11/2017)...  The global market for liquid biopsy diagnostic and ... in 2016.  Although in early stages, the global market ... as a result of the gradual shift towards personalized ... of a significant number of new liquid biopsy tests ... biomarkers to guide treatment decisions. ...
(Date:7/11/2017)... , July 11, 2017 Oramed Pharmaceuticals ... a clinical-stage pharmaceutical company focused on the development of ... Food and Drug Administration (FDA) has agreed to schedule ... completed Phase IIb trial of its oral insulin capsule ... Phase IIb trial met primary and secondary endpoints by ...
Breaking Medicine Technology:
Cached News: